NIH and Lilly to generate public resource of approved and investigational medicines
The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant testing systems, NIH announced today.
Comprehensive knowledge of the biological profiles of these medicines and molecules may enable biomedical researchers to better predict treatment outcomes, improve drug development, and lead to more specific and effective approaches.
Through the collaboration, the NIH's newly established National Center for Advancing Translational Sciences (NCATS) and Lilly Research Laboratories have agreed that NCATS' Pharmaceutical Collection of 3,800 approved and investigational medicines will be screened using Lilly's state-of-the-art Phenotypic Drug Discovery (PD2) panel. This panel features assays (i.e. tests) that are designed to reveal novel mechanisms or pathways of potential medicines and, as part of this collaboration, approved medicines as well. As such, the panel may provide new insights for drug discovery.
"This innovative collaboration with Lilly is exactly the type of partnership that NCATS is eager to foster with many other groups from industry, government and academia," said NCATS Acting Director Thomas R. Insel, M.D. "Working together, we can make drug development pipelines more productive. The key is precompetitive collaboration to benefit all partners, ensuring broad access to the results."
The NCATS Pharmaceutical Collection (NPC) is a comprehensive publicly available database and is a physical sample collection. The PD2 assay panel, part of Lilly's Open Innovation Drug Discovery platform, consists of sophisticated human disease pathway-related assays relevant to cardiovascular diseases, cancer and endocrine disorders, among others. These testing systems are designed to reveal novel mechanisms or pathway activities of drugs.
"This profiling, broad in terms of the therapeutics tested and the range and complexity of the biological readouts, will leverage the NPC in just the way I envisioned when we assembled the pharmaceutical collection," said Christopher P. Austin, M.D., director of the NCATS Division of Preclinical Innovation. "The combination of the power of the PD2 component of Lilly's Open Innovation Drug Discovery platform and the NPC will benefit of the entire scientific community."
The screening will take place over the next 12 to 18 months, and results will be made freely available at tripod.nih.gov/npc/. For example, if an approved medicine is found to be a possible treatment candidate for a new disease indication, a partnership with the organization that owns the chemical compound could be formed to pursue additional studies. These might include clinical trials required for marketing approval by the U.S. Food and Drug Administration. Alternatively, medicines with activity in the PD2 assays might serve as starting points for additional chemistry research efforts to produce new medicines.
"This initiative is a great example of how we can collectively leverage unique capabilities from the public and private sectors toward our shared goal of advancing science and improving patients' lives," said Alan D. Palkowitz, Ph.D., vice president of discovery chemistry research and technologies at Lilly. "It also attests to the importance of collaborative research because, despite major advances in biomedical science, much work remains to be done."
Provided by National Institutes of Health
-
NIH researchers create comprehensive collection of approved drugs to identify new therapies
Apr 27, 2011 |
not rated yet |
0
-
Mississippi sues pharmaceutical company
Jul 25, 2006 |
not rated yet |
0
-
Mississippi sues pharmaceutical company
Jul 25, 2006 |
not rated yet |
0
-
Eli Lilly may drop inhaled insulin plan
Mar 10, 2008 |
not rated yet |
0
-
Lilly, Boehringer collaborate on diabetes drugs
Jan 11, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
6 hours ago
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
15 hours ago |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
17 hours ago |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
22 hours ago |
not rated yet |
0
Succesful results in developing oral vaccine against diarrhea
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Medications
May 22, 2013 |
not rated yet |
0
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications
May 21, 2013 |
4.2 / 5 (5) |
0
Cold plasma successful against brain cancer cells
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...
Study reveals active site of enzyme linked to stuttering
(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...
Are kids who take music lessons different from other kids?
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
New discovery in fight against deadly meningococcal disease
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
Key find for early bladder cancer treatment
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.
Common brain processes of anesthetic-induced unconsciousness identified
A study from the June issue of Anesthesiology found feedback from the front region of the brain is a crucial building block for consciousness and that its disruption is associated with unconsciousness when the anesthetics ketami ...